Clonazepam and Metabolite, Serum
Use
This test is primarily used for monitoring clonazepam levels in patients under treatment. Clonazepam is commonly prescribed for the management of seizures and treatment of panic disorder. Measuring the drug levels ensures that therapeutic levels are achieved and maintained, avoiding potential toxicity associated with high concentrations. The assay also quantifies 7-amino clonazepam, the primary metabolite, providing a comprehensive understanding of the drug's pharmacokinetics in the patient.
Special Instructions
Each order must be accompanied by a separate specimen; sharing of specimens is not permitted. It is crucial to adhere to the specific collection instructions to ensure accurate results.
Limitations
This test has not been cleared or approved by the U.S. Food and Drug Administration, as it was developed and its performance characteristics determined by NMS Labs. Results might be influenced by improper specimen collection or handling, potentially leading to rejection. Serum collected in polymer gel tubes is unacceptable due to potential interference. Ensure samples are refrigerated or appropriately frozen to maintain specimen stability.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
LOINC Codes
- 3494-2
- 28059-4
Result Turnaround Time
7-11 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.3 mL
Container
Plastic, preservative-free vial
Collection Instructions
Centrifuge and send 1 mL of serum refrigerated in a plastic vial.
Causes for Rejection
Received room temperature; Polymer gel separation tube (SST or PST).
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 30 days |